Last reviewed · How we verify
A second dose with an 1 year interval
A booster vaccination dose administered one year after initial immunization to maintain or enhance immune protection.
A booster vaccination dose administered one year after initial immunization to maintain or enhance immune protection. Used for Booster immunization (specific indication unknown without additional product information).
At a glance
| Generic name | A second dose with an 1 year interval |
|---|---|
| Sponsor | Shanghai Municipal Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
This represents a second-dose vaccination schedule with a 12-month interval between the primary and booster doses. The booster is designed to restimulate the immune system and maintain or increase antibody titers and cellular immunity against the target pathogen. This dosing interval is typical for vaccines requiring sustained long-term protection.
Approved indications
- Booster vaccination (specific indication unknown without additional product information)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- Lung Cancer Prevention Screening Programme in Italy (NA)
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa (PHASE2)
- Safety and Early Signs of Efficacy of IL12-L19L19. (PHASE1)
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (PHASE3)
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (PHASE1)
- Korea Comirnaty Post-marketing Surveillance
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: